Triciribine (NSC 154020)

For research use only. Not for use in humans.

目录号:S1117 别名: VD-0002, vqd-002, API-2, TCN 中文名称:曲西立滨

Triciribine (NSC 154020) Chemical Structure

CAS No. 35943-35-2

Triciribine (NSC 154020, VD-0002, vqd-002, API-2, TCN) 是一种DNA synthesis抑制剂,也抑制PC3细胞系中的Akt和CEM-SS,H9,H9IIIB,U1细胞中的HIV-1IC50分别为130 nM和20 nM;对PI3K/PDK1没有抑制作用;作用于缺乏腺苷激酶的细胞,活性降低5000倍。Phase 1/2。

规格 价格 库存 购买数量  
10mM (1mL in DMSO) RMB 1235.93 现货
RMB 984.87 现货
RMB 4673.78 现货
RMB 13677.3 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck生产的Triciribine (NSC 154020)发表文献30篇:

产品安全说明书

Akt抑制剂选择性比较

生物活性

产品描述 Triciribine (NSC 154020, VD-0002, vqd-002, API-2, TCN) 是一种DNA synthesis抑制剂,也抑制PC3细胞系中的Akt和CEM-SS,H9,H9IIIB,U1细胞中的HIV-1IC50分别为130 nM和20 nM;对PI3K/PDK1没有抑制作用;作用于缺乏腺苷激酶的细胞,活性降低5000倍。Phase 1/2。
靶点
HIV-1 [2]
(CEM-SS, H9, H9IIIB, U1 cells)
Akt [1]
(PC3 cells)
20 nM 130 nM
体外研究

Triciribine的剂量为1-10 μM时生长抑制的效果最佳。像dosnstream p70S6K一样Triciribine基本在100μM (IC50 = 130 nM)时可以抑制Akt的磷酸化作用。Triciribine抑制Nf1和Trp53突变的肿瘤星型细胞的生长,这种抑制具有梯度依赖的特性。Triciribine在GI50为1.7 μM时并不能完全抑制(最高可抑制率为69%)WHO II K1861-10系的生长,而对于更高级的肿瘤系(KR158, KR130, and SF295), Triciribine可以在更低的GI50值(0.4–1.1 mM)时产生更广泛的抑制(最高抑制率>80%)。重要的是Triciribine能特异性地抑制肿瘤细胞而对大多数普通的星形胶质细胞抑制效率很低(GI50¼13.6 mM) [1]。Triciribine能抑制HIV-1, IC50为20 nM。用量为0.1μM时能产生>90%的抑制率,用量为5μM时能完全抑制多核体的形成。 在相同的细胞系中相关的细胞毒性实验结果显示当 Triciribine 浓度为46 μM时的选择性指数为2250. 利用HIV-1急性感染的CEM-SS, h9, 和 持续感染的H9III B 和 U1 细胞研究发现, Triciribine 可以显著的抑制HIV-1诱导的 p24 核心抗原的产生, 反转录酶和传染性病毒的产生,这种抑制具有剂量依赖的特性[2]。 Triciribine会抑制人前列腺癌PC-3 细胞系中的Akt 308位的酸酸和473位丝氨酸的磷酸化 以及Akt 的活性. Triciribine使PC-3 细胞对于TRAIL- 和 anti-CD95诱导的细胞凋亡更加敏感, 但是对于能引起DNA损伤的化疗依然具有抗性[3]。Triciribine 对于Akt具有高度的选择性,并不会抑制其它激酶的激活,如磷脂酰肌醇3激酶, 磷酸肌醇依赖的激酶1, 蛋白激酶C, serumand 糖皮质激素诱导激酶, 蛋白激酶 A, 信号传感器 和转录3 活化剂, 胞外信号调节激酶1/2或者c-Jun NH2-末端 激酶[4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
L1210 MmPqSpVv[3Srb36gZZN{[Xl? MYrU[ZN1\WRiaX6geol1em9iZn;yJIN6fG:2b4jpZ4l1gSCjZ3HpcpN1KG23cnnu[UBNOTJzMDDs[ZVs\W2rYzDj[YxteyxiSVO1NF0xNjB|Nd88US=> NH3FW4w9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zMEi4NlM4OSd-MUC4PFI{PzF:L3G+
HFF M3XydWZ2dmO2aX;uJIF{e2G7 M2\UcmhEVVZicHzhdZVmKGG|c3H5JJdieyCyZYLmc5Ju\WRidYPpcochUE[IIHPlcIx{KGGwZDDl[oZm[3Rid3HzJINidGO3bHH0[YQh[XNiYTDw[ZJk\W62YXflJI9nKHKnZIXjeIlwdiCrbjDueY1j\XJib3[gdIxieXWnczygTWM2OD1{LkZOwG0> MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yODh6MkO3NUc,OTB6OEKzO|E9N2F-
BSC-1 NFXYUlJCdnSrdnnyZYwh[XO|YYm= NIDo[FJCdnSrdnnyZYwh[WO2aY\peJkhf2G|IITld5Rm\CC3c3nu[{BidiCnbor5cYUudGmwa3XkJIludXWwb4PvdoJmdnRiYYPzZZkhMEWOSWPBLUB1dyCmZYTlZ5QhUFOYLUGgLIhmenCnczDzbY1xdGW6II\pdpV{KHS7cHWgNUkhfXOrbnegRnNENTFiY3XscJMtKEmFNUC9NlPPxE1? M4jS[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzFyOEiyN|cyLz5zMEi4NlM4OTxxYU6=
HFF NXnP[Y9nSW62aY\pdoFtKGG|c3H5 M1nQRmFvfGm4aYLhcEBi[3Srdnn0fUBi\2GrboP0JGhEVVZid3HzJIRmfGW{bXnu[YQh[nlicHzhdZVmKHKnZIXjeIlwdiCjc4PhfUB2e2mwZzDISmYh[2WubIOsJGlEPTB;Mj61{txO Mk[5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTB6OEKzO|MoRjFyOEiyN|c{RC:jPh?=
AA2 NH\hN4JHfW6ldHnvckBie3OjeR?= MnLmOUBpenN? M{DrRmlvfHKjY3XscJVt[XJicHjvd5Bpd3K7bHH0bY9vKChzMECgeW0qKGmwIIXubY5n\WO2ZXSgRWEzKGOnbHzzJJdieyC|dIXkbYVlKGGodHXyJFUhcHK|IH;mJGlv[3WkYYTpc44vNCCFb37j[Y51emG2aX;uQVnPxE1? NFjOV2Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zMEi4NlM4Oyd-MUC4PFI{PzN:L3G+
BSC-1 MWjBcpRqfmm{YXygZZN{[Xl? MoDGRY51cX[rcnHsJIFkfGm4aYT5JIFo[Wmwc4SgTHNXNTFid3HzJIRmfGW{bXnu[YQhfXOrbnegRnNENTFiY3XscJMh[nliYX6g[Y57gW2nLXzpcotm\CCrbX31co9{d3KkZX70JIF{e2G7IDjFUGlUSSluIFnDOVA:OjQQvF2= NYrEOnJjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUC4PFI{PzNpPkGwPFgzOzd|PD;hQi=>
Huh-7 MYHGeY5kfGmxbjDhd5NigQ>? MkDkR49ueG:3bnSge4F{KHSnc4Tl[EBnd3JiaYTzJIFjcWyrdImgeI8hcW6qaXLpeEBp\XCjdHn0bZMhSyC4aYLhcEBTVkFicnXwcIlk[XSrb36gbY4hUHWqLUegZ4VtdHNiKHj1cYFvKGincHH0c41iKGOnbHzzLUwhTUN3ME2y{txO M{jUeVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF3MUe3OFY1Lz5zNUG3O|Q3PDxxYU6=
MCF7 MVzDfZRwfG:6aXPpeJkh[XO|YYm= NXXse2tkS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVUOINzDj[YxteyCrbjDwdoV{\W6lZTDv[kAzOCC3TTDjbIxwem:zdXnu[UBjgSCVUlKgZZN{[XluIFfJOVA:OC5yNd88US=> M1flXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6NkmxPFk1Lz5zOE[5NVg6PDxxYU6=
MCF7 MV;DfZRwfG:6aXPpeJkh[XO|YYm= NIPqU|BEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBOS0Z5IHPlcIx{KGmwIIDy[ZNmdmOnIH;mJFExKHWPIHPocI9zd3G3aX7lJIJ6KFOUQjDhd5NigSxiR1m1NF0xNjV4zszN NUewfZNqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi2PVE5QTRpPkG4OlkyQDl2PD;hQi=>
MDA-MB-231 MmH4R5l1d3SxeHnjbZR6KGG|c3H5 NVPh[mx2S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVUSDLV3CMVI{OSClZXzsd{BqdiCycnXz[Y5k\SCxZjCyNEB2VSClaHzvdo9yfWmwZTDifUBUWkJiYYPzZZktKEeLNUC9NE43Qc7:TR?= MmH2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh4OUG4PVQoRjF6NkmxPFk1RC:jPh?=
MCF7 M{TCc2N6fG:2b4jpZ4l1gSCjc4PhfS=> NWrUXnhrS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVUOINzDj[YxteyCkeTDTVmIh[XO|YYmsJGdKPTB;Mz62OO69VQ>? NVHHcWdYRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi2PVE5QTRpPkG4OlkyQDl2PD;hQi=>
MDA-MB-468 NVqzcoM6S3m2b4TvfIlkcXS7IHHzd4F6 NHy1SoZEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBOTEFvTVKtOFY5KGOnbHzzJIlvKHC{ZYPlcoNmKG:oIEKwJJVOKGOqbH;yc5F2cW6nIHL5JHNTSiCjc4PhfUwhT0l3ME2xNE4zQc7:TR?= NUe0eXdCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi2PVE5QTRpPkG4OlkyQDl2PD;hQi=>
184B5 NHTkZYhEgXSxdH;4bYNqfHliYYPzZZk> M{PWRVIxKHWP NYmwOY5JS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hOTh2QkWgZ4VtdHNiYYSgNlAhfU1iY3jsc5JweXWrbnWgZpkhW1KEIHHzd4F6NCCJSUWwQVE3Njl4zszN M4D0VlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6NkmxPFk1Lz5zOE[5NVg6PDxxYU6=
MDA-MB-468 NHnNV3FEgXSxdH;4bYNqfHliYYPzZZk> MnzENVAhfU1? NULxTHJSS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVUSDLV3CMVQ3QCClZXzsd{BqdiCycnXz[Y5k\SCxZjCxNEB2VSClaHzvdo9yfWmwZTDifUBUWkJiYYPzZZktKEeLNUC9NlAvPDYQvF2= NW\hXGtjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi2PVE5QTRpPkG4OlkyQDl2PD;hQi=>
184B5 Mlq0R5l1d3SxeHnjbZR6KGG|c3H5 MV:xNEB2VQ>? M1LpSGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJFE5PEJ3IHPlcIx{KGG2IEGwJJVOKGOqbH;yc5F2cW6nIHL5JHNTSiCjc4PhfUwhT0l3ME2zOO69VQ>? MkfBQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh4OUG4PVQoRjF6NkmxPFk1RC:jPh?=
MDA-MB-231 NHnHPVBEgXSxdH;4bYNqfHliYYPzZZk> MV6xNEB2VQ>? MXjDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDNSGEuVUJvMkOxJINmdGy|IHnuJJBz\XOnbnPlJI9nKDFyIIXNJINpdG:{b4H1bY5mKGK7IGPSRkBie3OjeTygS2k2OD1|N988US=> NUDOfodtRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi2PVE5QTRpPkG4OlkyQDl2PD;hQi=>
184B5 MX;DfZRwfG:6aXPpeJkh[XO|YYm= MnH0R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gNVg1SjViY3XscJMh[nliU2LCJIF{e2G7LDDHTVUxRTRyzszN NGTEXWg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOE[5NVg6PCd-MUi2PVE5QTR:L3G+
MDA-MB-468 NU[yPFdnS3m2b4TvfIlkcXS7IHHzd4F6 M1mwVWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG1FSS2PQj20Olgh[2WubIOgZpkhW1KEIHHzd4F6NCCJSUWwQVQ{NjV|zszN MkDsQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh4OUG4PVQoRjF6NkmxPFk1RC:jPh?=
MDM NWrlSXdSSW62aY\pdoFtKGG|c3H5 MkLFOkBl[Xm| MXzBcpRqfmm{YXygZYN1cX[rdImgZYdicW6|dDDIeY1idiCrbX31co9l\W[rY3nlcoN6KH[rcoXzJFEhSUSDIHnu[oVkfGWmIHnuJIh2dWGwIF3EUUBk\WyuczDhd5Nme3OnZDDhd{BmgHC{ZYPzbY9vKG:oIICyOEBidnSrZ3XuJIFnfGW{IE[g[IF6eyCyb4P0bY5n\WO2aX;uJIJ6KEWOSWPBMEBKSzVyPUCuNFA3|ryP M3vHWlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyMEi2NVQ6Lz5{MEC4OlE1QTxxYU6=
ACH2 M{LqNmN6fG:2b4jpZ4l1gSCjc4PhfS=> M4\MWWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGFEUDJiY3XscJMhcW6oZXP0[YQhf2m2aDDsZZRmdnRiSIXtZY4hcW2vdX7v[IVncWOrZX7jfUB3cXK3czCxJIJ6KE2WUzDhd5NigSxiQ1O1NF0xNjBzzszN NYXSWYhjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkCwPFYyPDlpPkKwNFg3OTR7PD;hQi=>
ACH2 MYLDfZRwfG:6aXPpeJkh[XO|YYm= M3PpS2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGFEUDJiY3XscJMhcW6oZXP0[YQhf2m2aDDsZZRmdnRiSIXtZY4hcW2vdX7v[IVncWOrZX7jfUB3cXK3czCxJIJ6KE2WUzDhd5NigSCrbjDwdoV{\W6lZTDv[kB1fW2xcjDu[YNzd3OrczDmZYN1d3JiYXzwbIEtKEOFNUC9NE4xOc7:TR?= NIf3Zpo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEC4OlE1QSd-MkCwPFYyPDl:L3G+
CEM-SS NWGyU4NsSW62aY\pdoFtKGG|c3H5 NIPicIM3KGSjeYO= M3jqS2FvfGm4aYLhcEBi[3Srdnn0fUBi\2GrboP0JGh2dWGwIHntcZVvd2SnZnnjbYVv[3lidnnyeZMhOSB|QjDpcoZm[3SnZDDpckBpfW2jbjDDSW0uW1NiY3XscJMhcW6oZXP0[YQhf2m2aDCwMlc5KHWOIH;mJJZqenW|IIP0c4NsKGG|c3Xzd4VlKGG|IHX4dJJme3Orb36gc4YheDJ2IHHueIlo\W5iYX\0[ZIhPiCmYYnzJJBwe3Srbn\lZ5Rqd25iYomgSWxKW0FuIFnDOVA9OC5yMd88US=> NILDT|Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEC4OlE1QSd-MkCwPFYyPDl:L3G+
MDM MWLBcpRqfmm{YXygZZN{[Xl? M3LBc|Yh\GG7cx?= MUTBcpRqfmm{YXygZYN1cX[rdImgZYdicW6|dDDIeY1idiCrbX31co9l\W[rY3nlcoN6KH[rcoXzJFEhSkGOIHnu[oVkfGWmIHnuJIh2dWGwIF3EUUBk\WyuczDhd5Nme3OnZDDhd{BmgHC{ZYPzbY9vKG:oIICyOEBidnSrZ3XuJIFnfGW{IE[g[IF6eyCyb4P0bY5n\WO2aX;uJIJ6KEWOSWPBMEBKSzVyPUCuNFE5|ryP MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODB6NkG0PUc,OjByOE[xOFk9N2F-
H9 NYXhTYc{SW62aY\pdoFtKGG|c3H5 MnvaRY51cX[rcnHsJIFkfGm4aYT5JIFo[Wmwc4SgTJVu[W5iaX3teY5w\GWoaXPp[Y5kgSC4aYL1d{AyKFONMTDpcoZm[3SnZDDpckBpfW2jbjDIPUBk\WyuczDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oII\pdoFtKFKndnXyd4UhfHKjboPjdolxfGG|ZTDifUBcO0ifVGTQJIlv[2:{cH;yZZRqd25iYYPzZZktKEmFNUC9NE4xOzcQvF2= MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODB6NkG0PUc,OjByOE[xOFk9N2F-
CEM-SS NWXBXVdYSW62aY\pdoFtKGG|c3H5 M4T4OmFvfGm4aYLhcEBi[3Srdnn0fUBi\2GrboP0JGh2dWGwIHntcZVvd2SnZnnjbYVv[3lidnnyeZMhOSB|QjDlfJBz\XO|aX7nJI5m\iCycn;0[YlvKGmwZnXjeIlv\yCrbjDDSW0uW1NiY3XscJMh[XO|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kB3cXKjbDDS[ZZmenOnIITyZY5{[3KrcIThd4Uh[nliW{PIYXRVWCCrbnPvdpBwemG2aX;uJIF{e2G7LDDJR|UxRTBwMEVOwG0> M4fIclxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyMEi2NVQ6Lz5{MEC4OlE1QTxxYU6=
CEM-SS M4PEfmFvfGm4aYLhcEBie3OjeR?= NFPiTnNCdnSrdnnyZYwh[WO2aY\peJkh[WejaX7zeEBJfW2jbjDpcY12dm:mZX\pZ4lmdmO7II\pdpV{KDFiM1KgbY5n\WO2ZXSgbY4hcHWvYX6gR2VONVOVIHPlcIx{KGmwZnXjeIVlKHerdHigNE44QCC3TDDv[kB3cXK3czDzeI9kcyCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKH[rcnHsJHJmfmW{c3WgeJJidnOlcnnweIF{\SCkeTDbN2heXFSSIHnuZ49zeG:{YYTpc44h[XO|YYmsJGlEPTB;MD6wPO69VQ>? M3PpeFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyMEi2NVQ6Lz5{MEC4OlE1QTxxYU6=
H9 M{HPdWFvfGm4aYLhcEBie3OjeR?= M4LMVGFvfGm4aYLhcEBi[3Srdnn0fUBi\2GrboP0JGh2dWGwIHntcZVvd2SnZnnjbYVv[3lidnnyeZMhOSB|QjDpcoZm[3SnZDDpckBpfW2jbjDIPUBk\WyuczDpcoZm[3SnZDD3bZRpKDJ3IIXMJI9nKH[rcoXzJJN1d2OtIHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZidnnyZYwhWmW4ZYLz[UB1emGwc3PybZB1[XOnIHL5JHs{UF2WVGCgbY5kd3Kyb4LheIlwdiCjc4PhfUwhUUN3MEywMlHPxE1? MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODB6NkG0PUc,OjByOE[xOFk9N2F-
H9 MVHBcpRqfmm{YXygZZN{[Xl? NU\NTpFpSW62aY\pdoFtKGGldHn2bZR6KGGpYXnud5QhUHWvYX6gbY1ufW6xZHXmbYNq\W6leTD2bZJ2eyBzIEPCJIlv\mWldHXkJIlvKGi3bXHuJGg6KGOnbHzzJIlv\mWldHXkJJdqfGhiMUKuOUB2VCCxZjD2bZJ2eyC|dH;jb{Bie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJJZqemGuIGLleoVze2VidILhcpNkemmydHHz[UBjgSCdM1jdWHRRKGmwY3;ydI9z[XSrb36gZZN{[XluIFnDOVA9OC5zzszN M3u3V|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyMEi2NVQ6Lz5{MEC4OlE1QTxxYU6=
H9 M1zBUGFvfGm4aYLhcEBie3OjeR?= MnHiRY51cX[rcnHsJIFkfGm4aYT5JIFo[Wmwc4SgTJVu[W5iaX3teY5w\GWoaXPp[Y5kgSC4aYL1d{AyKDOEIHnu[oVkfGWmIHnuJIh2dWGwIFi5JINmdGy|IHnu[oVkfGWmIIfpeIghPi5{NTD1UEBw\iC4aYL1d{B{fG:lazDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oII\pdoFtKFKndnXyd4UhfHKjboPjdolxfGG|ZTDifUBcO0ifVGTQJIlv[2:{cH;yZZRqd25iYYPzZZktKEmFNUC8NE4y|ryP MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODB6NkG0PUc,OjByOE[xOFk9N2F-
H9 MW\BcpRqfmm{YXygZZN{[Xl? MUS2JIRigXN? MUHBcpRqfmm{YXygZYN1cX[rdImgZYdicW6|dDDIeY1idiCrbX31co9l\W[rY3nlcoN6KH[rcoXzJFEhO0JiaX7m[YN1\WRiaX6gbJVu[W5iSEmgZ4VtdHNiaX7m[YN1\WRid3n0bEAyOi53IIXMJI9nKH[rcoXzJJN1d2OtIHHzd4V{e2WmIHHzJIV5eHKnc4Ppc44hd2ZicEK0JIFvfGmpZX6gZYZ1\XJiNjDkZZl{KHCxc4TpcoZm[3Srb36gZpkhTUyLU1GsJGlEPTB:MD6x{txO NVXDdlNTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkCwPFYyPDlpPkKwNFg3OTR7PD;hQi=>
H9 Moi1RY51cX[rcnHsJIF{e2G7 MmHoOkBl[Xm| MYrBcpRqfmm{YXygZYN1cX[rdImgZYdicW6|dDDIeY1idiCrbX31co9l\W[rY3nlcoN6KH[rcoXzJFEhO0JiaX7m[YN1\WRiaX6gbJVu[W5iSEmgZ4VtdHNiaX7m[YN1\WRid3n0bEA3NjJ3IIXMJI9nKH[rcoXzJJN1d2OtIHHzd4V{e2WmIHHzJIV5eHKnc4Ppc44hd2ZicEK0JIFvfGmpZX6gZYZ1\XJiNjDkZZl{KHCxc4TpcoZm[3Srb36gZpkhTUyLU1GsJGlEPTB:MD6x{txO NH3OZXg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEC4OlE1QSd-MkCwPFYyPDl:L3G+
CEM-SS NXnaOoJkSW62aY\pdoFtKGG|c3H5 MX;BcpRqfmm{YXygZYN1cX[rdImgZYdicW6|dDDIeY1idiCrbX31co9l\W[rY3nlcoN6KH[rcoXzJFEhW0tzIHnu[oVkfGWmIHnuJIh2dWGwIFPFUU1UWyClZXzsd{Bie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJJZqemGuIGLleoVze2VidILhcpNkemmydHHz[UBjgSCdM1jdWHRRKGmwY3;ydI9z[XSrb36gZZN{[XluIFnDOVA:OC5zM988US=> NXHmT|lwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkCwPFYyPDlpPkKwNFg3OTR7PD;hQi=>
ACH2 MXLBcpRqfmm{YXygZZN{[Xl? M3rGfVMh\GG7cx?= MkTHRY51cX[rcnHsJIFkfGm4aYT5JIFo[Wmwc4SgOUB5KDFyJ{OgZ4VtdHNxd3XscEBJfW2jbjDpcY12dm:mZX\pZ4lmdmO7II\pdpV{KDFiaX7m[YN1\WRiaX6gbJVu[W5iQVPINkBk\WyuczDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oII\pdoFtKFKndnXyd4UhfHKjboPjdolxfGG|ZTDh[pRmeiB|IHThfZMh[nliW{PIYXRVWCCrbnPvdpBwemG2aX;uJIF{e2G7IHnuJJBz\XOnbnPlJI9nKDVibnevcYwhfHWvb4KgcoVkem:|aYOg[oFkfG:{IHHsdIhiNCCLQ{WwQVAvOTYQvF2= NXHuUVBjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkCwPFYyPDlpPkKwNFg3OTR7PD;hQi=>
AA5 MlzQRY51cX[rcnHsJIF{e2G7 M2fiTGFvfGm4aYLhcEBi[3Srdnn0fUBi\2GrboP0JI9nKEi3bXHuJIludXWwb3Tl[olkcWWwY4mgeolzfXNiMTCzRkBqdm[nY4Tl[EBqdiCDQUWgZ4VtdHNiaX7m[YN1\WRid3n0bEA{NjF|IIXMJI9nKH[rcoXzJJN1d2OtIHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZidnnyZYwhWmW4ZYLz[UB1emGwc3PybZB1[XOnIHL5JHs{UF2WVGCgbY5kd3Kyb4LheIlwdiCjc4PhfUwhUUN3MEywMlE4|ryP MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODB6NkG0PUc,OjByOE[xOFk9N2F-
AA5 NFu2UGRCdnSrdnnyZYwh[XO|YYm= M2XwO2FvfGm4aYLhcEBi[3Srdnn0fUBi\2GrboP0JI9nKEi3bXHuJIludXWwb3Tl[olkcWWwY4mgeolzfXNiMTCzRkBqdm[nY4Tl[EBqdiCDQUWgZ4VtdHNiaX7m[YN1\WRid3n0bEAyNjV4IIXMJI9nKH[rcoXzJJN1d2OtIHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZidnnyZYwhWmW4ZYLz[UB1emGwc3PybZB1[XOnIHL5JHs{UF2WVGCgbY5kd3Kyb4LheIlwdiCjc4PhfUwhUUN3MEywMlE4|ryP MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODB6NkG0PUc,OjByOE[xOFk9N2F-
AA5 MXfBcpRqfmm{YXygZZN{[Xl? NFrr[oxCdnSrdnnyZYwh[WO2aY\peJkh[WejaX7zeEBw\iCKdX3hckBqdW23bn;k[YZq[2mnbnP5JJZqenW|IEGgN2IhcW6oZXP0[YQhcW5iQVG1JINmdGy|IHnu[oVkfGWmIIfpeIghOC55ODD1UEBw\iC4aYL1d{B{fG:lazDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oII\pdoFtKFKndnXyd4UhfHKjboPjdolxfGG|ZTDifUBcO0ifVGTQJIlv[2:{cH;yZZRqd25iYYPzZZktKEmFNUC8NE4yP87:TR?= NF[3UnU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEC4OlE1QSd-MkCwPFYyPDl:L3G+
CEM-SS MmHFRY51cX[rcnHsJIF{e2G7 NFTrcGE3KGSjeYO= NInTUo9CdnSrdnnyZYwh[WO2aY\peJkh[WejaX7zeEBJfW2jbjDpcY12dm:mZX\pZ4lmdmO7II\pdpV{KDFiM1KgbY5n\WO2ZXSgbY4hcHWvYX6gR2VONVOVIHPlcIx{KGmwZnXjeIVlKHerdHigNU42PiC3TDDv[kB3cXK3czDzeI9kcyCjc4Pld5Nm\CCjczDlfJBz\XO|aX;uJI9nKHB{NDDhcpRq\2WwIHHmeIVzKDZiZHH5d{Bxd3O2aX7m[YN1cW:wIHL5JGVNUVODLDDJR|UxRTBwMUpOwG0> M4PnelxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyMEi2NVQ6Lz5{MEC4OlE1QTxxYU6=
CEM-SS MlnERY51cX[rcnHsJIF{e2G7 MlnRRY51cX[rcnHsJIFkfGm4aYT5JIFo[Wmwc4SgTJVu[W5iaX3teY5w\GWoaXPp[Y5kgSC4aYL1d{AyKGijcnLvdolv\yCybHHzcYllKE6OND2zJIlv\mWldHXkJIlvKEOHTT3TV{Bk\WyuczDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oII\pdoFtKFKndnXyd4UhfHKjboPjdolxfGG|ZTDifUBcO0ifVGTQJIlv[2:{cH;yZZRqd25iYYPzZZktKEmFNUC9NE4z|ryP MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODB6NkG0PUc,OjByOE[xOFk9N2F-
U1 NGjDNmhCdnSrdnnyZYwh[XO|YYm= NGfycXhCdnSrdnnyZYwh[WO2aY\peJkh[WejaX7zeEBJfW2jbjDpcY12dm:mZX\pZ4lmdmO7II\pdpV{KDFiaX7m[YN1\WRiaX6gbJVu[W5iVUGgZ4VtdHNiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iC4aYLhcEBT\X[ncoPlJJRz[W6|Y4LpdJRie2ViYomgX|NJZVSWUDDpcoNwenCxcnH0bY9vKGG|c3H5MEBKSzVyPUCuNlPPxE1? M2q5VFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyMEi2NVQ6Lz5{MEC4OlE1QTxxYU6=
CEM-SS NWnnWWM1SW62aY\pdoFtKGG|c3H5 MU[2JIRigXN? NEHmWVFCdnSrdnnyZYwh[WO2aY\peJkh[WejaX7zeEBJfW2jbjDpcY12dm:mZX\pZ4lmdmO7II\pdpV{KDFiM1KgbY5n\WO2ZXSgbY4hcHWvYX6gR2VONVOVIHPlcIx{KGmwZnXjeIVlKHerdHigN{4yOyC3TDDv[kB3cXK3czDzeI9kcyCjc4Pld5Nm\CCjczDlfJBz\XO|aX;uJI9nKHB{NDDhcpRq\2WwIHHmeIVzKDZiZHH5d{Bxd3O2aX7m[YN1cW:wIHL5JGVNUVODLDDJR|UxRTBwMkVOwG0> NEn2UXU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEC4OlE1QSd-MkCwPFYyPDl:L3G+
U1 NXO5cplGS3m2b4TvfIlkcXS7IHHzd4F6 MmrVR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gWVEh[2WubIOgbY5n\WO2ZXSge4l1cCCuYYTlcpQhUHWvYX6gbY1ufW6xZHXmbYNq\W6leTD2bZJ2eyBzIHL5JG1VWyCjc4PhfUwhS0N3ME2wMlI5|ryP MmXTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjByOE[xOFkoRjJyMEi2NVQ6RC:jPh?=
U1 NGjrenhEgXSxdH;4bYNqfHliYYPzZZk> NE\XWm9EgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBWOSClZXzsd{Bqdm[nY4Tl[EB4cXSqIHzheIVvfCCKdX3hckBqdW23bn;k[YZq[2mnbnP5JJZqenW|IEGgZpkhVVSVIHHzd4F6KGmwIIDy[ZNmdmOnIH;mJJR2dW:{IH7lZ5Jwe2m|IH\hZ5RweiCjbIDoZUwhS0N3ME2wMlI5|ryP MorpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjByOE[xOFkoRjJyMEi2NVQ6RC:jPh?=
CEM-SS MX7BcpRqfmm{YXygZZN{[Xl? NXLNdYpySW62aY\pdoFtKGGldHn2bZR6KGGpYXnud5QhUHWvYX6gbY1ufW6xZHXmbYNq\W6leTD2bZJ2eyBzIEPCJIlv\mWldHXkJIlvKGi3bXHuJGNGVS2VUzDj[YxteyCrbn\lZ5Rm\CC5aYToJFEvPTZidVygc4Yhfmm{dYOgd5Rw[2tiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iC4aYLhcEBT\X[ncoPlJJRz[W6|Y4LpdJRie2ViYomgX|NJZVSWUDDpcoNwenCxcnH0bY9vKGG|c3H5MEBKSzVyPUCuNlnPxE1? MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODB6NkG0PUc,OjByOE[xOFk9N2F-
CEM-SS NXv6[oUzSW62aY\pdoFtKGG|c3H5 NXjkcVVJSW62aY\pdoFtKGGldHn2bZR6KGGpYXnud5QhUHWvYX6gbY1ufW6xZHXmbYNq\W6leTD2bZJ2eyBzIEPCJIlv\mWldHXkJIlvKGi3bXHuJGNGVS2VUzDj[YxteyCrbn\lZ5Rm\CC5aYToJFMvOTNidVygc4Yhfmm{dYOgd5Rw[2tiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iC4aYLhcEBT\X[ncoPlJJRz[W6|Y4LpdJRie2ViYomgX|NJZVSWUDDpcoNwenCxcnH0bY9vKGG|c3H5MEBKSzVyPUCuN:69VQ>? MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODB6NkG0PUc,OjByOE[xOFk9N2F-
CEM-SS M3jCPGFvfGm4aYLhcEBie3OjeR?= MmP6RY51cX[rcnHsJIFkfGm4aYT5JIFo[Wmwc4SgTJVu[W5iaX3teY5w\GWoaXPp[Y5kgSC4aYL1d{AyKERzIHjhdoJwemmwZzDUfZIyOjeKaYOgcZV1[XSrb36gbY4hdmWoIIDyc5RmcW5iaX7m[YN1cW6pIHnuJGNGVS2VUzDj[YxteyCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKH[rcnHsJHJmfmW{c3WgeJJidnOlcnnweIF{\SCkeTDbN2heXFSSIHnuZ49zeG:{YYTpc44h[XO|YYmsJGlEPTB;MD6zN:69VQ>? M4HxTVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyMEi2NVQ6Lz5{MEC4OlE1QTxxYU6=
CEM-SS NYD2Z49tSW62aY\pdoFtKGG|c3H5 MkXMRY51cX[rcnHsJIFkfGm4aYT5JIFo[Wmwc4SgTJVu[W5iaX3teY5w\GWoaXPp[Y5kgSC4aYL1d{AyKEF5IHjhdoJwemmwZzDUfZIyOjeKaYOgcZV1[XSrb36gbY4hdmWoIIDyc5RmcW5iaX7m[YN1cW6pIHnuJGNGVS2VUzDj[YxteyCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKH[rcnHsJHJmfmW{c3WgeJJidnOlcnnweIF{\SCkeTDbN2heXFSSIHnuZ49zeG:{YYTpc44h[XO|YYmsJGlEPTB;MD61{txO NW\idZB7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkCwPFYyPDlpPkKwNFg3OTR7PD;hQi=>
MDM MlXvR5l1d3SxeHnjbZR6KGG|c3H5 MnPKR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUWROKGOnbHzzJIlv\mWldHXkJJdqfGhiSIXtZY4hcW2vdX7v[IVncWOrZX7jfUB3cXK3czCxJGJCVCCkeTDNWHMh[XO|YYmsJHREPTB;MD62Ou69VQ>? MmThQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjByOE[xOFkoRjJyMEi2NVQ6RC:jPh?=
CEM-SS M4jONGFvfGm4aYLhcEBie3OjeR?= M2PhcGFvfGm4aYLhcEBi[3Srdnn0fUBi\2GrboP0JGh2dWGwIHntcZVvd2SnZnnjbYVv[3lidnnyeZMhOiCUT1SgbY5n\WO2ZXSgbY4hcHWvYX6gR2VONVOVIHPlcIx{KGG|c3Xzd4VlKGG|IHnubIljcXSrb36gc4Yhfmm{YXygVoV3\XK|ZTD0doFve2O{aYD0ZZNmKGK7IGuzTH1VXFBiaX7jc5Jxd3KjdHnvckBie3OjeTygTWM2OD1zLkVOwG0> NV\vN5NIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkCwPFYyPDlpPkKwNFg3OTR7PD;hQi=>
H9 MYnBcpRqfmm{YXygZZN{[Xl? MWfBcpRqfmm{YXygZYN1cX[rdImgZYdicW6|dDDIeY1idiCrbX31co9l\W[rY3nlcoN6KH[rcoXzJFEhO0JiaX7m[YN1\WRiaX6gbJVu[W5iSEmgZ4VtdHNiaX7m[YN1\WRid3n0bEA2OCC3TDDv[kB3cXK3czDzeI9kcyCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKH[rcnHsJHJmfmW{c3WgeJJidnOlcnnweIF{\SCkeTDbN2heXFSSIHnuZ49zeG:{YYTpc44h[XO|YYmsJGlEPTB;MT61N:69VQ>? NI\ZWGY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEC4OlE1QSd-MkCwPFYyPDl:L3G+
H9 MlvMR5l1d3SxeHnjbZR6KGG|c3H5 NFvlRYREgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBJQSClZXzsd{BjgSCPVGOgZZN{[XluIFnDOVA:OTZwM988US=> MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODB6NkG0PUc,OjByOE[xOFk9N2F-
H9 NVfyNodYS3m2b4TvfIlkcXS7IHHzd4F6 MXPDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDIPUBk\WyuczDifUBOXFNiYYPzZZktKEOFNUC9NVkvPs7:TR?= MoW0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjByOE[xOFkoRjJyMEi2NVQ6RC:jPh?=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
PUMA / p-FoxO3a / p-AKT ; 

PubMed: 20978166     


p53-KO cells were treated with the AKT inhibitor triciribine (1 μM) or MK-2206 (25 μM) for 1 hr (for analysis of p-FoxO3a and p-AKT) or 24 hr (for analysis of PUMA), and indicated proteins were analyzed by Western blotting.

20978166
Immunofluorescence
TRF2 / 53BP1 ; 

PubMed: 23862686     


TIF analysis of HTC75 cells serum starved (0.01% FBS) for 16 h or treated with triciribine (1µM) for 3 hours. Cells were immunostained with anti-53BP1 (red) and TRF2 (green) antibodies. DMSO-treated cells were used as controls. Arrows indicate overlapping foci. 

23862686
体内研究 Riciribine按照 1 mg/kg/天的剂量对裸小鼠腹腔注射,可以抑制 OVCAR3, OVCAR8 和 PANC1 肿瘤的生长, 分别使Akt过量表达了90%, 88% 和80%。 然而, Triciribine 对OVCAR5 和 COLO357细胞的生长基本没有影响[4]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验:[1]
- 合并

Akt磷酸化改变分析:

待细胞生长到全板80%–90%,加入1–10 ng/mL表皮生长因子(EGF; cat #01-107)或血小板生长因子(PDGF)–AA (cat #01-309) (Upstate Biotechnology)加入或者不加 10–20 mM的 U0126 (cat #EI-282) 或 LY-294002 (cat #ST-420) (Biomol Research Lab)刺激细胞5到10分钟。用12%–15% SDS PAGE分离5–20 μg蛋白裂解液,用Akt (cat #cs-9272), 磷酸化的 Akt (磷酸丝氨酸 473; cat #cs-9271), MAPK (cat #cs-9102)和磷酸化 MAPK (p44/42 磷酸苏氨酸202/Tyr204; cat #cs-01-9101)抗体1:1000稀释(Cell Signaling Technology)蛋白印迹检测蛋白裂解物。
细胞实验:[2]
- 合并
  • Cell lines: CEM-SS 细胞
  • Concentrations: 0-500 μM
  • Incubation Time: 48小时
  • Method: 将 CEM-SS细胞按1万个每孔的密度接种在96孔平板中并在生长培养基中培养,用上述细胞对triciribine的细胞毒性进行分析评定. 将连续稀释5倍的不同浓度的Triciribine加到细胞中. 37℃孵育48小时, 通过电转将细胞用含有放射性同位素3H的 dThd (1 μCi 每孔, 放射性比度为20 Ci/mmol)标记6小时,收取细胞并测定总的DNA合成量
    (Only for Reference)
动物实验:[4]
- 合并
  • Animal Models: 皮下注射OVCAR3, OVCAR8, PANC1, OVCAR5和 COLO357 肿瘤细胞的80周龄雌性裸小鼠.
  • Dosages: 1 mg/kg/天
  • Administration: 腹腔注射,一天一次.
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 64 mg/mL (199.81 mM)
Water Insoluble
Ethanol Insoluble
体内 从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
1% DMSO+30% polyethylene glycol+1% Tween 80
30 mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 320.3
化学式

C13H16N6O4

CAS号 35943-35-2
储存条件 粉状
溶于溶剂
别名 VD-0002, vqd-002, API-2, TCN

动物体内配方计算器 (澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)
% DMSO % % Tween 80 % ddH2O
计算重置

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、SDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、SDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT02987127 Unknown status -- Mucosa-Associated Lymphoid Tissue Lymphoma National Taiwan University Hospital February 2016 --
NCT00642031 Completed Drug: Triciribine Hematologic Malignancies|Leukemia Prescient Therapeutics Ltd.|VioQuest Pharmaceuticals August 2006 Phase 1

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

Akt Signaling Pathway Map

Akt Inhibitors with Unique Features

相关Akt产品

Tags: 购买Triciribine (NSC 154020) | Triciribine (NSC 154020)供应商 | 采购Triciribine (NSC 154020) | Triciribine (NSC 154020)价格 | Triciribine (NSC 154020)生产 | 订购Triciribine (NSC 154020) | Triciribine (NSC 154020)代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID